Galera Therapeutics, Inc. 8-K

What Happened Galera Therapeutics, Inc. (GRTX) filed an 8-K (Item 8.01) disclosing two related equity events in early April 2026. On April 7, 2026 the company completed a partial mandatory conversion of 76,479.175 shares of its Series B Non‑Voting Convertible Preferred Stock into 76,479,164 shares of common stock under the Certificate of Designation; no fractional common shares were issued and holders will be paid cash for any fractional amounts per the Certificate. On April 8, 2026 certain affiliates of Ikarian Capital, LLC exercised pre‑funded warrants to buy 8,488,229 shares of common stock at $0.001 per share, for aggregate proceeds of approximately $8,488.23 to the company.

Key Details

• Conversion date: April 7, 2026 — 76,479.175 Series B preferred → 76,479,164 common shares.
• Post-conversion Series B outstanding: 42,839.11 shares.
• Warrant exercise date: April 8, 2026 — 8,488,229 pre‑funded warrants exercised at $0.001/share; cash received ≈ $8,488.23.
• Remaining pre‑funded warrants outstanding after exercise: 14,552,811 shares.

Why It Matters These actions change the company’s capital structure by increasing common shares outstanding and reducing preferred and warrant overhang. The warrant exercise provided only a small cash infusion (~$8.5k). Investors should note the updated counts of common shares, remaining Series B preferred shares, and outstanding pre‑funded warrants when assessing dilution and ownership percentages. For precise share‑count impact, refer to Galera’s subsequent filings or investor relations disclosures for updated fully diluted share totals.